Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial.

Authors : Powles RL, Redmond D, Sotiriou C, Loi S, Fumagalli D, Nuciforo P, Harbeck N, de Azambuja E, Sarp S, Di Cosimo S, Huober J, Baselga J, Piccart-Gebhart M, Elemento O, Pusztai L, Hatzis C
Year : 2018
Journal : JAMA Oncol
Volume : 4
Pages : e181564

Neoadjuvant treatment: the future of patients with breast cancer.

Authors : Reyal F, Hamy AS, Piccart-Gebhart M
Year : 2018
Journal : ESMO Open
Volume : 3
Pages : e000371

Treatment of advanced HER2-positive breast cancer: 2018 and beyond.

Authors : Pondé N, Brandão M, El-Hachem G, Werbrouck E, Piccart-Gebhart M
Year : 2018
Journal : Cancer Treat Rev
Volume : 67
Pages : 10-20

Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes.

Authors : Spraggs CF, Parham LR, Briley LP, Warren L, Williams LS, Fraser DJ, Jiang Z, Aziz Z, Ahmed S, Demetriou G, Mehta A, Jackson N, Byrne J, Andersson M, Toi M, Harris L, Gralow J, Zujewski JA, Crescenzo R, Armour A, Perez E, Piccart-Gebhart M
Year : 2018
Journal : Pharmacogenomics J
Volume : 18
Pages : 480-486

Capecitabine efficacy is correlated with TYMP and RB expression in PDX established from triple-negative breast cancers.

Authors : Marangoni E, Laurent C, Coussy F, El Botty R, Chateau-Joubert S, Servely JL, de Plater L, Assayag F, Dahmani A, Montaudon E, Némati F, Fleury J, Vacher S, Gentien D, Rapinat A, Foidart P, Sounni NE, Noël A, Salomon A, Lae M, Decaudin D, Roman-Roman S, Bièche I, Piccart-Gebhart M, Reyal F
Year : 2018
Journal : Clin Cancer Res
Volume : 24(11)
Pages : 2605-2615

Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.

Authors : Bareche Y, Venet D, Ignatiadis M, Aftimos P, Piccart-Gebhart M, Rothé F, Sotiriou C
Year : 2018
Journal : Ann Oncol
Volume : 29(4)
Pages : 895-902

Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).

Authors : Ponde N, Bradbury I, Lambertini M, Ewer M, Campbell C, Ameels H, Zardavas D, Di Cosimo S, Baselga J, Huober J, Izquierdo M, Fumagalli D, Bozovic-Spasojevic I, Maetens M, Harbeck N, Pusztai L, Berghorn M, Im YH, Borrego MR, Chen DR, Rodeheffer R, Piccart-Gebhart M, Suter T, de Azambuja E
Year : 2018
Journal : Breast Cancer Res Treat
Volume : 168(3)
Pages : 631-638

The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO.

Authors : Di Cosimo S, Campbell C, Azim HA Jr, Galli G, Bregni G, Curigliano G, Criscitiello C, Izquierdo M, de la Pena L, Fumagalli D, Fein L, Vinholes J, Ng WMJ, Colleoni M, Ferro A, Naume BJ, Patel A, Huober J, Piccart-Gebhart M, Baselga J, de Azambuja E
Year : 2018
Journal : Eur J Cancer
Volume : 89
Pages : 42-48

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials.(autors : Early Breast Cancer Trialists'Collaborative Group)

Authors : Early Breast Cancer Trialists Collaborative Group, + collaborators (among others :, Piccart-Gebhart M
Year : 2018
Journal : Lancet Oncol
Volume : 19
Pages : 27-39

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.

Authors : Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I, Gómez HL, Tondini C, Ciruelos E, Burstein HJ, Bonnefoi HR, Bellet M, Martino S, Geyer CE Jr, Goetz MP, Stearns V, Pinotti G, Puglisi F, Spazzapan S, Climent MA, Pavesi L, Ruhstaller T, Davidson NE, Coleman R, Debled M, Buchholz S, Ingle JN, Winer EP, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber Rd, Goldhirsch A, Regan MM, + collaborators (among others :, Piccart-Gebhart M
Year : 2018
Journal : N Engl J Med
Volume : 379
Pages : 122-137

Risk factors for the development of brain metastases in patients with HER2-positive breast cancer.

Authors : Maurer C, Tulpin L, Moreau M, Dumitrescu C, de Azambuja E, Paesmans M, Nogaret JM, Piccart-Gebhart M, Awada A
Year : 2018
Journal : ESMO Open
Volume : 3
Pages : e000440

Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review.

Authors : Pe M, Dorme L, Coens C, Basch E, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, Dirven L, Dueck AC, Devlin N, Flechtner HH, Gotay C, Griebsch I, Groenvold M, King M, Koller M, Malone DC, Martinelli F, Mitchell SA, Musoro JZ, Oliver K, Piault-Louis E, Piccart-Gebhart M, Pimentel FL, Quinten C, Reijneveld JC, Sloan J, Velikova G, Bottomley A
Year : 2018
Journal : Lancet Oncol
Volume : 19
Pages : e459-e469

Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials.

Authors : Bottomley A, Pe M, Sloan J, Basch E, Bonnetain F, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, Dueck AC, Devlin N, Flechtner HH, Gotay C, Greimel E, Griebsch I, Groenvold M, Hamel JF, King M, Kluetz PG, Koller M, Malone DC, Martinelli F, Mitchell SA, Moinpour CM, Musoro JZ, OConnor D, Oliver K, Piault-Louis E, Piccart-Gebhart M, Pimentel FL, Quinten C, Reijneveld JC, Schürmann C, Smith AW, Soltys KM, Sridhara R, Taphoorn MJB, Velikova G, Coens C
Year : 2018
Journal : Clin Trials
Volume : 15
Pages : 624-630

Long-Term Clinical Outcome and Survivorship Issues of High Grade Bone Sarcomas

Authors : Closset C, Ameye L, Gebhart M, de Saint-Aubain de Somerhausen N, Beauvois S, Awada A, Piccart-Gebhart M, Gil T
Year : 2018
Journal : Int J cancer and oncology
Volume : 5(1)
Pages : 26-34

Reply to: Re-Aligning the ASCO and ESMO Clinical Benefit Frameworks or Modern Cancer Therapies.

Authors : Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, Tabernero J, Zielinski C, Piccart-Gebhart M, de Vries EGE
Year : 2017
Journal : Ann Oncol
Volume : 29(3):
Pages : 774-775

Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer.

Authors : Solinas C, Garaud S, De Silva P, Boisson A, Van den Eynden G, de Wind A, Risso P, Rodrigues Vitória J, Richard F, Migliori E, Noël G, Duvillier H, Craciun L, Veys I, Awada A, Detours V, Larsimont D, Piccart-Gebhart M, Willard-Gallo K
Year : 2017
Journal : Front Immunol
Volume : 8
Pages : 1412

Charcot-Marie-Tooth hereditary neuropathy revealed after administration of docetaxel in advanced breast cancer.

Authors : Kourie HR, Mavroudakis N, Aftimos P, Piccart-Gebhart M
Year : 2017
Journal : World J Clin Oncol
Volume : 8
Pages : 425-428

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).

Authors : Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, de Vries EGE, Piccart-Gebhart M
Year : 2017
Journal : Ann Oncol
Volume : 28
Pages : 2901-2905

Adenoid cystic carcinoma of the breast - an aggressive presentation with pulmonary, kidney, and brain metastases: a case report.

Authors : Mhamdi HA, Kourie HR, Jungels C, Aftimos P, Belbaraka R, Piccart-Gebhart M
Year : 2017
Journal : J Med Case Rep
Volume : 11
Pages : 303

Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules.

Authors : Dafni U, Karlis D, Pedeli X, Bogaerts J, Pentheroudakis G, Tabernero J, Zielinski CC, Piccart-Gebhart M, de Vries EGE, Latino NJ, Douillard JY, Cherny NI
Year : 2017
Journal : ESMO Open
Volume : 2
Pages : e000216